Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus recommendation of “Hold” by the twenty-two research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $20.3913.

A number of analysts have weighed in on the stock. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $5.00 price target (down from $12.00) on shares of Intellia Therapeutics in a report on Friday. Robert W. Baird set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, October 30th. Barclays reduced their target price on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. Royal Bank Of Canada lowered their price target on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Friday. Finally, JMP Securities cut their price target on Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a report on Tuesday, October 28th.

Intellia Therapeutics Stock Down 22.7%

Shares of NASDAQ:NTLA opened at $9.52 on Friday. The business has a 50 day moving average price of $17.19 and a 200 day moving average price of $12.47. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -2.23 and a beta of 2.44. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million during the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative return on equity of 56.28% and a negative net margin of 774.94%.Intellia Therapeutics’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.34) earnings per share. Analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NTLA. CWM LLC grew its holdings in shares of Intellia Therapeutics by 4.7% in the 3rd quarter. CWM LLC now owns 19,187 shares of the company’s stock worth $331,000 after purchasing an additional 856 shares during the last quarter. Federated Hermes Inc. boosted its position in Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after buying an additional 927 shares in the last quarter. Cyndeo Wealth Partners LLC boosted its position in Intellia Therapeutics by 9.3% in the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock valued at $202,000 after buying an additional 995 shares in the last quarter. Benjamin Edwards Inc. grew its stake in Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after buying an additional 1,126 shares during the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Intellia Therapeutics by 8.2% during the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company’s stock worth $120,000 after buying an additional 1,282 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.